These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 8233270

  • 21. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K.
    Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
    [Abstract] [Full Text] [Related]

  • 22. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L, Tempfer C, Häusler G, Heinzl H, Kainz C.
    Wien Klin Wochenschr; 1998 Oct 02; 110(18):635-41. PubMed ID: 9816636
    [Abstract] [Full Text] [Related]

  • 23. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D.
    J BUON; 2007 Oct 02; 12(1):99-104. PubMed ID: 17436409
    [Abstract] [Full Text] [Related]

  • 24. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ, Lang JH, Shen K, Wang L, Wu M, Xu XY.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan 02; 43(1):9-12. PubMed ID: 18366924
    [Abstract] [Full Text] [Related]

  • 25. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
    Lawicki S, Bedkowska E, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Pol Merkur Lekarski; 2008 Jul 02; 25(145):38-42. PubMed ID: 18839612
    [Abstract] [Full Text] [Related]

  • 26. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M, Wong GY, Nisselbaum JS, Almadrones L, Hoskins WJ, Rubin SC.
    Obstet Gynecol; 1993 Jun 02; 81(6):989-92. PubMed ID: 8497368
    [Abstract] [Full Text] [Related]

  • 27. [Selected hematopoietic cytokines in patients with colorectal cancer].
    Mroczko B, Ławicki S, Szmitkowski M, Czygier M, Okulczyk B, Piotrowski Z.
    Pol Merkur Lekarski; 2003 Nov 02; 15(89):416-9. PubMed ID: 14969133
    [Abstract] [Full Text] [Related]

  • 28. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A, Szirmai K, Oláh J, Papp Z, Jeney A.
    Orv Hetil; 2004 Aug 01; 145(31):1617-24. PubMed ID: 15384859
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic value of serum VEGF in women with ovarian tumors.
    Oehler MK, Caffier H.
    Anticancer Res; 1999 Aug 01; 19(4A):2519-22. PubMed ID: 10470186
    [Abstract] [Full Text] [Related]

  • 30. Macrophage migration inhibitory factor expression in ovarian cancer.
    Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G.
    Am J Obstet Gynecol; 2007 Apr 01; 196(4):348.e1-5. PubMed ID: 17403417
    [Abstract] [Full Text] [Related]

  • 31. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
    Elg S, Halberg E, Ramakrishnan S, Cornélissen G, Haus E, Nicolau G, Carson L, Twiggs L, Long HJ, Halberg F.
    Chronobiologia; 1991 Apr 01; 18(4):141-52. PubMed ID: 1687728
    [Abstract] [Full Text] [Related]

  • 32. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
    Gadducci A, Ferdeghini M, Prontera C, Moretti L, Pellagatta L, Bianchi R, Fioretti P.
    J Nucl Biol Med (1991); 1991 Apr 01; 35(1):33-7. PubMed ID: 1657201
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y, Fujiwara H, Akagaki E, Hirota K, Kono M, Irie T, Miura S, Okudaira Y.
    Gan To Kagaku Ryoho; 1986 Jan 01; 13(1):46-52. PubMed ID: 3455806
    [Abstract] [Full Text] [Related]

  • 35. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
    Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE.
    J Clin Oncol; 2005 Dec 20; 23(36):9338-43. PubMed ID: 16361633
    [Abstract] [Full Text] [Related]

  • 36. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
    Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC.
    Am J Obstet Gynecol; 1991 Nov 20; 165(5 Pt 1):1356-62. PubMed ID: 1957862
    [Abstract] [Full Text] [Related]

  • 37. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX, Schwartz PE, Li FQ.
    Obstet Gynecol; 1990 Apr 20; 75(4):701-4. PubMed ID: 2179784
    [Abstract] [Full Text] [Related]

  • 38. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S, Gerber B, Briese V.
    Anticancer Res; 2007 Apr 20; 27(4A):1837-9. PubMed ID: 17649781
    [Abstract] [Full Text] [Related]

  • 39. Circulating macrophage colony stimulating factor as a marker of tumour progression.
    McDermott RS, Deneux L, Mosseri V, Védrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouillart P, Scholl SM.
    Eur Cytokine Netw; 2002 Apr 20; 13(1):121-7. PubMed ID: 11956031
    [Abstract] [Full Text] [Related]

  • 40. Postmenopausal changes in serum cytokine levels and hormone replacement therapy.
    Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T, Aono T.
    Am J Obstet Gynecol; 2001 Feb 20; 184(3):309-14. PubMed ID: 11228479
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.